NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call
NeuroMetrix (NURO) will release its second quarter financial results on July 21, 2022, before market open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeuroMetrix (NURO) will release its second quarter financial results on July 21, 2022, before market open. A conference call discussing these results and relevant business developments is scheduled for the same day at 8:00 a.m. ET. Interested participants can access the call through an audio-only webcast available on the company’s website. NeuroMetrix specializes in medical devices for neurological disorders and pain management, offering three main products: DPNCheck®, ADVANCE®, and Quell®.
Positive
- Plans to release Q2 financial results on July 21, 2022.
- Scheduled conference call for stakeholder engagement.
Negative
- None.
Details
News Market Reaction – NURO
The recorded move for NURO in the trading session of this news was +4.67%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WOBURN, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 second quarter financial results before the opening of the market on July 21, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on July 21, 2022 to discuss its financial results as well as business developments affecting the Company.
An audio-only webcast of the call, along with the earnings press release and accompanying condensed financial statements, may be accessed in the Investors section of the Company’s website at www.NeuroMetrix.com. Under a new procedure, participants who wish to access the call live via telephone to ask questions must register in advance here. Upon registering, a dial-in and unique PIN will be provided on screen and via email to join the call. Following the conference call, a replay of the call will be available for one year on the Company's website at www.NeuroMetrix.com under the "Investor Relations" tab.
About NeuroMetrix
NeuroMetrix is an innovation-driven company with a mission to improve individual and population health through innovative medical devices and technology solutions for neurological disorders and pain syndromes. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell® is a wearable neuromodulation technology indicated for treatment of fibromyalgia symptoms and chronic lower extremity pain. For more information, visit www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.